Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
- 30 January 2026
- journal article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 472-479
Abstract
Background: Neoadjuvant chemotherapy (NAC) with gemcitabine and S‐1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear. Methods: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non‐elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence‐free survival (RFS), and overall survival (OS). Results: A total of 185 patients were included (non‐elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S‐1 was lower in elderly patients, RFS and OS did not significantly differ between groups. Conclusions: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.Keywords
This publication has 16 references indexed in Scilit:
- Optimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19‐9 DynamicsJournal of Surgical Oncology, 2025
- Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective studyMedicine, 2024
- Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancerJapanese Journal of Clinical Oncology, 2021
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerNew England Journal of Medicine, 2018
- Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patientsClinica Chimica Acta, 2018
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017Pancreatology, 2018
- Evaluation of Modified Glasgow Prognostic Score for Pancreatic CancerPancreas, 2016
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992